ESMO 2021 | VESPER: dd-MVAC as perioperative chemotherapy for MIBC

Enrique Grande, MD, PhD, MD Anderson Cancer Center Madrid, Madrid, Spain, discusses the results of the GETUG/AFU VESPER V05 trial (NCT01812369), a Phase III trial investigating the optimal perioperative chemotherapy regimen for patients with muscle-invasive bladder cancer (MIBC). Patients were randomized to receive either 4 cycles of GC every three weeks of 6 cycles of dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) every 2 weeks before surgery (neoadjuvant group) or after surgery (adjuvant group). In the neoadjuvant group, a better bladder tumour local control with a significant improvement in PFS at 3 years being observed in the dd-MVAC arm. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.